Nuveen’s Marker Therapeutics MRKR Stock Holding History

Nuveen’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-19,257	Closed	-$431K	–	3475
2021 Q1	$431K	Sell	19,257 -384	-2%	-$8.79K	﹤0.01%	3120
2020 Q4	$285K	Sell	19,641 -74	-0.4%	-$1.15K	﹤0.01%	3141
2020 Q3	$295K	Sell	19,715 -1,836	-9%	-$33.5K	﹤0.01%	3091
2020 Q2	$446K	Buy	21,551 +12,296	+133%	+$269K	﹤0.01%	2946
2020 Q1	$176K	Buy	9,255 +2,264	+32%	+$57.7K	﹤0.01%	3014
2019 Q4	$201K	Buy	6,991 +71	+1%	+$2.58K	﹤0.01%	3078
2019 Q3	$354K	Hold	6,920	–	–	﹤0.01%	3025
2019 Q2	$548K	Buy	+6,920	New	+$411K	﹤0.01%	2973

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's MRKR Position: Q2 2021 in Review

Nuveen sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 19,257 shares — an estimated $431K sold.

Nuveen first reported a position in MRKR in Q2 2019 and held it in 8 quarters. The position peaked at $548K in Q2 2019. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

Nuveen reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
Nuveen sold 19,257 Marker Therapeutics shares in Q2 2021, an estimated $431K.
Nuveen first reported a position in Marker Therapeutics in Q2 2019 and held it in 8 quarters.
Nuveen's Marker Therapeutics position peaked at $548K in Q2 2019.
74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.